MEDICAL RADIOLOGICAL DEFENSE (ACD&P)
Abstract
Operational forces have an immediate need to survive, safely operate, and sustain operations in a radiological/nuclear (R/N) threat environment across a continuum of global, contingency, special operations/low intensity conflict, homeland defense, and other high-risk missions. Exposure to ionizing radiation causes acute radiation syndrome (ARS) which includes damage to blood-forming cells (hematopoietic system), gastrointestinal system, and central nervous system. Treatment of R/N casualties depends on effective use of multiple medical capabilities in an integrated manner. There are currently no FDA-approved prophylactic, therapeutic, or biodosimetry capabilities against ARS. Thus, this program supports the development of medical radiological countermeasures (MRADC) using a family-of-systems approach to provide a full spectrum medical capability including prophylactics, therapeutics, and biodosimetry to protect Warfighters against the radiation threat and to mitigate the medical consequences of exposure to ionizing radiation. MRADC efforts include development of multiple countermeasures to prevent, limit, or reverse the myriad of injuries caused by exposure to radiation resulting in increased survival, decreased incapacity, and sustained operational effectiveness of U.S. Forces. In addition, MRADC will be effective against a broad range of ionizing radiation sources and types and will be useable throughout the full spectrum of healthcare operations.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2014
- Source ID
- MR4_0603884BP_4_0400_PB_2014
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (ACD&P)
- Child Accomplishment: 1) MRADC
- Child Accomplishment: 2) MRADC
- Child Cost Item: 97f714734d9e6af88fac4d48d3f09b49
- Child Cost Item: b019c90803cfc5651ed2e7a4330ccf2f
- Child Cost Item: e893741d504cada22edadadbe9c06a35
- Child Cost Item: 524b1af5888b18aabdb550dd03888f09